Lutetium-177 Therapy for Prognostic Marker Evaluation in Castration-Resistant Prostate Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035087

Enrollment

400

Registered

2024-09-17

Start date

2024-01-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Clinical findings, laboratory values and imaging data collected as part of the clinical routine at baseline as well as dynamically during radioligand therapy with Lu-177-PSMA for mCRPC will b

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with metastatic castration-resistant prostate cancer treated with Lu-177-PSMA radioligand therapy at the University Hospital Bonn between 2009 and 2023

Exclusion criteria

Exclusion criteria: No imaging examination as part of diagnostics and/or therapy monitoring

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS)	—

Secondary

Measure	Time frame
Radiographic Progression-free Survival (rPFS) PSA decrease >90% (PSA90) Objective Response Rate (ORR)	—

Countries

Germany

Contacts

Public ContactThomas Büttner

Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn

thomas.buettner@ukbonn.de+49 228 287 16030

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026